Vericel (VCEL) Intangibles (2014 - 2026)
Vericel (VCEL) posted Intangibles of $5.3 million for Q2 2026, down 2.85% sequentially from $5.5 million in Q1 2026, and down 10.53% YoY from $5.9 million in Q2 2025.
Vericel (VCEL) Intangibles (2014 - 2026) Analysis & Trends
Vericel has reported Intangibles for 8 years, with the latest figure at $5.3 million in Q2 2026.
- Quarterly Intangibles fell 10.53% year-over-year to $5.3 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was $5.3 million (down 10.53% YoY) and the FY2025 annual result came in at $5.6 million, down 10.0% from the prior year.
- Intangibles eased to $5.3 million in Q2 2026 per VCEL's latest filing, from $5.5 million in the prior quarter.
- Over five years, Intangibles peaked at $7.5 million in Q4 2022 and troughed at $5.3 million in Q2 2026.
- A 5-year average of $6.4 million and a median of $6.4 million in 2024 frame the typical range for Intangibles.
- The sharpest annual moves came in 2023 and 2026: Intangibles dropped 8.33% in 2023, then slipped 10.53% in 2026.
- Over 5 years, Intangibles stood at $7.5 million in 2022, then fell by 8.33% to $6.9 million in 2023, then dropped by 9.09% to $6.2 million in 2024, then declined by 10.0% to $5.6 million in 2025, then dropped by 5.55% to $5.3 million in 2026.
- According to Business Quant data, Intangibles over the past three periods registered $5.3 million, $5.5 million, and $5.6 million for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Intangibles (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 412.80 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.31 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 266.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 63.28 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 60.96 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | - |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | - |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 93.49 Mn |
| 10 | Vericel | 2.26 Bn | 2.10 Bn | 56.40 Mn | 5.31 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 5.31 Mn |
| Mar 31, 2026 | 5.47 Mn |
| Dec 31, 2025 | 5.63 Mn |
| Sep 30, 2025 | 5.78 Mn |
| Jun 30, 2025 | 5.94 Mn |
| Mar 31, 2025 | 6.09 Mn |
| Dec 31, 2024 | 6.25 Mn |
| Sep 30, 2024 | 6.41 Mn |
| Jun 30, 2024 | 6.56 Mn |
| Mar 31, 2024 | 6.72 Mn |
| Dec 31, 2023 | 6.88 Mn |
| Sep 30, 2023 | 7.03 Mn |
| Jun 30, 2023 | 7.19 Mn |
| Mar 31, 2023 | 7.34 Mn |
| Dec 31, 2022 | 7.50 Mn |
| Sep 30, 2016 | 2.71 Mn |
| Jun 30, 2016 | 2.78 Mn |
| Mar 31, 2016 | 2.85 Mn |
| Dec 31, 2015 | 2.92 Mn |
| Sep 30, 2015 | 2.99 Mn |